Cresco Labs (CL) Aandelenoverzicht
Cresco Labs Inc. kweekt, produceert en verkoopt cannabisproducten voor de detailhandel en medische toepassingen in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
CL Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeCresco Labs Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | CA$1.38 |
| 52 Week Hoogtepunt | CA$3.12 |
| 52 Week Laag | CA$0.60 |
| Bèta | 1.65 |
| 1 maand verandering | 2.99% |
| 3 maanden verandering | -4.17% |
| 1 Jaar Verandering | 9.52% |
| 3 jaar verandering | -39.74% |
| 5 jaar verandering | -91.08% |
| Verandering sinds IPO | -78.93% |
Recent nieuws en updates
CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.
CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook
Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.Recent updates
CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook
Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.CL: Higher Future P/E Assumptions Will Shape A More Upside-Skewed Outlook
Analysts have lowered their price target on Cresco Labs to CA$2.25 from CA$2.50, reflecting updated views on revenue growth, profit margins, and a much higher assumed future P/E multiple. Analyst Commentary Bearish analysts are signaling a more cautious stance on Cresco Labs by trimming their price target to CA$2.25 from CA$2.50, even while still seeing speculative upside potential.CL: Expanded Retail Footprint And Flexible Equity Program Will Support A More Optimistic Outlook
Analysts have revised their price target on Cresco Labs to CA$16.91 from CA$18.36, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Cresco Labs filed a follow on equity offering for up to CA$140 million of Subordinate Voting Shares through an at the market program, giving the company flexibility to raise capital over time (Key Developments).Cresco Labs Inc. (CSE:CL) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
Feb 12
CL: Expanded Retail And EU Entry Will Support A More Optimistic Outlook
Analysts have lifted their price target on Cresco Labs to US$1.94 from US$1.51, citing revised assumptions around revenue growth, profit margins, discount rate, and a lower future P/E multiple as key drivers of the change. What's in the News Cresco Labs filed a follow on equity offering of up to C$140 million in subordinate voting shares through an at the market program, adding flexibility to raise capital as needed (Key Developments).CL: New German Entry Will Support Future Upside
Analysts have nudged their price target for Cresco Labs higher, now implying fair value of about $2.40 per share versus roughly $2.36 previously. The change reflects updated views on revenue growth, profit margins and future P/E assumptions.CL: German Entry And Higher Margins Will Support Future Upside
Analysts have raised their price target for Cresco Labs from US$2.30 to about US$2.36, reflecting updated views on the company’s profit margin outlook and a lower assumed future P/E multiple. What's in the News Cresco Labs launched Cresco branded flower in Germany, marking its first commercial entry into the European Union and extending its growth plans beyond the U.S. cannabis market (Key Developments).CL: Expanded Retail And European Entry Will Support Stronger Profitability
Analysts have modestly raised their price target on Cresco Labs to reflect an updated fair value estimate of approximately 2.30 dollars, up from about 2.16 dollars previously, citing expectations for stronger revenue growth, improved profit margins, a slightly lower discount rate, and a more reasonable future earnings multiple. What's in the News Entered the European Union with the launch of Cresco branded flower in Germany, using the market as a testbed for broader international expansion beyond U.S. cannabis (Key Developments).Cresco Labs Inc. (CSE:CL) Not Doing Enough For Some Investors As Its Shares Slump 37%
Nov 26Here's Why Cresco Labs (CSE:CL) Is Weighed Down By Its Debt Load
Nov 08Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 35% But Growth Is Lacking
Oct 12Is Cresco Labs Inc. (CSE:CL) Trading At A 49% Discount?
Sep 06Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 27% But Growth Is Lacking
Jul 31Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt
Jul 23Cresco Labs Inc.'s (CSE:CL) 30% Share Price Plunge Could Signal Some Risk
Jun 15Cresco Labs Inc.'s (CSE:CL) Shares Climb 31% But Its Business Is Yet to Catch Up
May 01
Expanding Production In Illinois, Pennsylvania And Kentucky Will Meet Demand
Expansion in Illinois and Pennsylvania and entry into Kentucky's market aim to boost revenue growth and market share.Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 27%
Mar 07Is Cresco Labs (CSE:CL) A Risky Investment?
Jan 31Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Dec 14Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely
Oct 24Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Aug 11Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?
Jul 17Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden
Jun 19Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 19Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41
Mar 16Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%
Mar 03Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt
Jan 26Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)
Jan 04Rendement voor aandeelhouders
| CL | CA Pharmaceuticals | CA Markt | |
|---|---|---|---|
| 7D | -13.8% | -4.7% | -0.9% |
| 1Y | 9.5% | 43.4% | 34.6% |
Rendement versus industrie: CL presteerde slechter dan de Canadian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 43.4 % opleverde.
Rendement versus markt: CL presteerde slechter dan Canadian Market, dat het afgelopen jaar een rendement van 34.6 % opleverde.
Prijsvolatiliteit
| CL volatility | |
|---|---|
| CL Average Weekly Movement | 17.8% |
| Pharmaceuticals Industry Average Movement | 12.3% |
| Market Average Movement | 10.4% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.9% |
Stabiele aandelenkoers: De aandelenkoers van CL is de afgelopen 3 maanden volatiel geweest in vergelijking met de Canadian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 18% ) van CL is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Canadian.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| n/a | 2,900 | Charlie Bachtell | www.crescolabs.com |
Cresco Labs Inc. kweekt, produceert en verkoopt cannabisproducten voor de detailhandel en medische toepassingen in de Verenigde Staten. Het bedrijf levert cannabis in de vorm van bloemen, vape pennen, levende harsen, wegwerppennen en extracten onder de merknaam Cresco; vape carts, vape pennen, bloem, popcorn, shake, pre-rolls, shorties en concentraten onder de merknaam High Supply; vapes en gummies onder de merknaam Good News; vapes en edibles onder de merknaam Wonder Wellness Co; en tincturen, capsules, zalven en sublinguale oliën onder de merknaam Remedi. Het bedrijf biedt cannabisbloemen aan onder de merknaam FloraCal; en cannabisoliën en een verscheidenheid aan hapjes zijn verkrijgbaar op meerdere potentieniveaus onder de merknaam Mindy's Edibles, evenals licenties voor de merknaam Kiva.
Cresco Labs Inc. Samenvatting
| CL fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | CA$678.16m |
| Inkomsten(TTM) | -CA$184.34m |
| Inkomsten(TTM) | CA$892.84m |
Is CL overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CL resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$655.85m |
| Kosten van inkomsten | US$331.28m |
| Brutowinst | US$324.57m |
| Overige uitgaven | US$459.98m |
| Inkomsten | -US$135.41m |
Laatst gerapporteerde inkomsten
Dec 31, 2025
Volgende inkomensdatum
May 08, 2026
| Winst per aandeel (EPS) | -0.37 |
| Brutomarge | 49.49% |
| Nettowinstmarge | -20.65% |
| Schuld/Eigen Vermogen Verhouding | 132.1% |
Hoe presteerde CL op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/04 14:52 |
| Aandelenkoers aan het einde van de dag | 2026/05/04 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Cresco Labs Inc. wordt gevolgd door 13 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Russell Stanley | Beacon Securities Limited |